JCI:脂质转录因子ChREBP介导果糖诱导的代谢适应,以预防肝毒性

2017-06-20 MedSci MedSci原创

流行病学和动物研究表明果糖在非酒精性脂肪肝疾病的发展中过度消耗,但是果糖诱导的慢性肝病的分子机制仍然在很大程度上是未知的。在这里,我们提出了支持脂肪转录因子碳水化合物反应元件结合蛋白(ChREBP),在介导对果糖的适应性反应和防止果糖诱导的肝毒性中的必须的功能的证据。

流行病学和动物研究表明果糖在非酒精性脂肪肝疾病的发展中过度消耗,但是果糖诱导的慢性肝病的分子机制仍然在很大程度上是未知的。在这里,我们提出了支持脂肪转录因子碳水化合物反应元件结合蛋白(ChREBP),在介导对果糖的适应性反应和防止果糖诱导的肝毒性中的必须的功能的证据。在WT小鼠中,高果糖饮食(HFrD)以ChREBP依赖的方式激活肝脂肪生成;然而,在Chrebp-KO小鼠中,HFrD可以诱导脂肪性肝炎。在Chrebp-KO小鼠肝脏中,HFrD降低了分子伴侣的水平,并激活了C / EBP同源蛋白依赖性(CHOP依赖性)解折叠蛋白反应,而施用化学伴侣或Chop shRNA可以挽救肝损伤。在HFrD喂养的Chrebp-KO肝脏中胆固醇生物合成基因的表达水平升高与甾醇调节元件结合蛋白2(SREBP2)的核丰度增加相平行。阿曲伐他汀介导的肝脏胆固醇生物合成抑制或肝脏Srebp2的消耗在Chrebp-KO小鼠中逆转果糖诱导的肝损伤。在机制上,我们确定ChREBP与核SREBP2结合以促进其在培养细胞中的泛素化和不稳定。因此,我们的研究结果表明,ChREBP通过防止胆固醇生物合成的过度活化和随后的CHOP介导的促凋亡解折叠蛋白反应来提供对HFrD的肝保护作用。我们的发现也确定了ChREBP在调节SREBP2依赖性胆固醇代谢中的作用。

原文出处:

Deqiang Q. Zhang,Xin Tong,et al.Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity.[J]J Clin Invest.doi:10.1172/JCI89934.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982069, encodeId=69f51982069b5, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Thu Jul 27 20:13:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747250, encodeId=93fc1e47250b6, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Mar 28 17:13:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537470, encodeId=8553153e4702a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622693, encodeId=4a231622693a1, content=<a href='/topic/show?id=c81d812342e' target=_blank style='color:#2F92EE;'>#肝毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81234, encryptionId=c81d812342e, topicName=肝毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982069, encodeId=69f51982069b5, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Thu Jul 27 20:13:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747250, encodeId=93fc1e47250b6, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Mar 28 17:13:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537470, encodeId=8553153e4702a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622693, encodeId=4a231622693a1, content=<a href='/topic/show?id=c81d812342e' target=_blank style='color:#2F92EE;'>#肝毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81234, encryptionId=c81d812342e, topicName=肝毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
    2018-03-28 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982069, encodeId=69f51982069b5, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Thu Jul 27 20:13:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747250, encodeId=93fc1e47250b6, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Mar 28 17:13:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537470, encodeId=8553153e4702a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622693, encodeId=4a231622693a1, content=<a href='/topic/show?id=c81d812342e' target=_blank style='color:#2F92EE;'>#肝毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81234, encryptionId=c81d812342e, topicName=肝毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982069, encodeId=69f51982069b5, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Thu Jul 27 20:13:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747250, encodeId=93fc1e47250b6, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Mar 28 17:13:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537470, encodeId=8553153e4702a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622693, encodeId=4a231622693a1, content=<a href='/topic/show?id=c81d812342e' target=_blank style='color:#2F92EE;'>#肝毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81234, encryptionId=c81d812342e, topicName=肝毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jun 22 04:13:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]

相关资讯

J Hepatol:警惕他汀类药物相关肝毒性

 冰岛和瑞典的一项研究显示,他汀类药物相关的特异质性肝损伤虽然罕见,但可以非常严重。如果恢复后再次用药,可再现同类型的肝损伤。大多数患者开始用他汀类药物3~4个月后发生肝损伤,阿托伐他汀最常发生胆汁淤积型肝损伤,而辛伐他汀更常见肝细胞损伤。本文发表于《肝脏病学杂志》[J Hepatol 2012,56(2):374]。   该研究对1988-2010年间瑞典药物不良反应顾问委员会收到的、怀疑由

Int J Clin Pharmacol Ther:拉克酰胺会诱导产生肝毒性

简介:拉克酰胺是一种新型的抗癫痫药物,作用主要是通过选择性增强电压依赖性钠离子通道的缓慢失活。据报道,拉克酰胺对部分癫痫患者的辅助治疗是有效的和可耐受的。很少有报道关于拉克酰胺引起的肝损伤。我们举一例耐药性癫痫患者服用拉克酰胺后发展为肝毒性的症状。结果: 22岁有2年颞叶癫痫历史的女性收纳至我们医院,因为恶心,头晕和检测到的肝功能异常。在当前的陈述病情下使用拉克酰胺用于进一步发作控制9天

J Antimicrob Chemother:TB/HIV共感染患者:抗TB药物浓度与肝毒性不相关

2017年1月,发表在《J Antimicrob Chemother》的一项由乌干达、瑞士和美国科学家进行的研究考察了TB/HIV共感染患者中,抗TB药物浓度和药物相关毒性。